Clinical Trials Logo

Filter by:
NCT ID: NCT06183905 Not yet recruiting - PROSTATE CANCER Clinical Trials

Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection

TRUSVSMPMRI
Start date: December 2023
Phase: N/A
Study type: Interventional

The goal of this cohort study is to investigate multiparametric ultrasound versus multiparametric MRI for clinically significant prostate cancer detection in patients scheduled for initial biopsy. The main questions it aims to answer are: - whether the clinically significant prostate cancer detection rate of multiparametric ultrasound is comparable to multiparametric MRI - the any cancer detection of multiparametric ultrasound versus multiparametric MRI Participants will undergo multiparametric ultrasound and multiparametric MRI before prostate biopsy. In case of suspicious findings on ultrasound or MRI, they will undergo combined systematic biopsy and targeted biopsy. In case of nonsuspicious imaging finding, they will undergo systematic biopsy alone.

NCT ID: NCT06183892 Not yet recruiting - Liver Transplant Clinical Trials

Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study aims to explore the effects of tacrolimus sustained-release capsules on the incidence of biopsy-proven acute rejection(BPAR) and fibrosis in pediatric liver transplant recipients.

NCT ID: NCT06183736 Not yet recruiting - Clinical trials for Advanced Solid Tumors

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.

NCT ID: NCT06182969 Not yet recruiting - SLE Clinical Trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

NCT ID: NCT06182852 Not yet recruiting - Diabete Type 2 Clinical Trials

The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus

Start date: January 1, 2024
Phase:
Study type: Observational

Through an one-year follow-up, to explore the effect of GLP-1 receptor agonist on bone metabolism in patients with diabetes.

NCT ID: NCT06182592 Not yet recruiting - Clinical trials for High-risk (Secondary) Acute Myeloid Leukemia

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

Start date: January 2024
Phase: Phase 3
Study type: Interventional

The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.

NCT ID: NCT06181526 Not yet recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis

SPECIALS
Start date: December 15, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, randomized, double-blind, placebo parallel-controlled, dose-escalation clinical study. The aim of this study was to evaluate the safety, tolerability, and preliminary effect of Aleeto in adult patients with ALS, and to provide an appropriate dose for the future clinical trial.

NCT ID: NCT06181448 Not yet recruiting - Clinical trials for Chronic Liver Disease and Cirrhosis

Real-World Validation of a Prognostic Prediction Model for Patients With Acute Exacerbations of Chronic Liver Disease

Start date: February 1, 2024
Phase:
Study type: Observational

Our study is a multi-site, prospective, observational study including patients with acute exacerbations of CLD. Approximately 1500 patients from 24 hospitals in diverse regions in China will be enrolled and followed for 3 months. Data about demographic data, laboratory tests, and clinical manifestations, collected through a mobile application, will inform real-time prognostic scores. The aim of this study is to validate the model's real-world applicability in non-specialist hospital settings.

NCT ID: NCT06178432 Not yet recruiting - Clinical trials for Pompe Disease (Late-onset)

Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)

Start date: December 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-center, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of CRG003 injection in participants with late onset Pompe disease (LOPD), with a long-term follow-up period of 5 years. CRG003 (BBM-G102) injection is an adeno-associated virus (AAV) gene therapy product for treating Pompe disease to stably express active GAA enzyme in the liver on a long-term basis after the injection.

NCT ID: NCT06178211 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Start date: December 2023
Phase: Phase 2
Study type: Interventional

The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC).